BioSpace News Archive

Aurum Biosciences has received approval from the UK regulatory authority for a Phase 2 clinical trial due to start in Q1 2018.

Eisai announced that it has created educational materials for understanding dementia and thinking about what one can do for elementary and secondary school students, and has commenced marketing these materials primarily to local governments, educational institutions as well as medical and nursing care professionals from today.

Rice University researchers have invented a device that uses fast-moving fluids to insert flexible, conductive carbon nanotube fibers into the brain, where they can help record the actions of neurons.

To access the live webcast, please visit Biogen’s Investors section at www.biogen.com/investors.

The round included several individual investors and former executives from Illumina, the world leader in DNA sequencing and array-based technologies.

The option grants entitle the employees, in aggregate, to purchase up to 89,000 shares of common stock at an exercise price per share of $3.51.